PMID- 33847358
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20240226
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 73
IP  - 9
DP  - 2021 Aug 12
TI  - Ganoderma lucidum ameliorates the diabetic nephropathy via down-regulatory effect 
      on TGFbeta-1 and TLR-4/NFkappaB signalling pathways.
PG  - 1250-1261
LID - 10.1093/jpp/rgab058 [doi]
AB  - OBJECTIVES: Diabetic nephropathy (DN) is one of the most important complications 
      of diabetes mellitus and it is considered as a principal cause for end-stage 
      renal failure. Ganoderma lucidum (GL) has been studied for its reno-protective 
      effect against different kidney injury models. The aim of our study is to 
      investigate the mechanisms by which GL can improve kidney injury and consequent 
      renal inflammation and fibrosis. METHODS: GL either in a low dose (250 mg/kg, 
      i.p.) or high dose (500 mg/kg, i.p.) was administered to DN rat model, and 
      nephropathy indices were investigated. KEY FINDINGS: GL treatment significantly 
      down-regulated kidney injury molecule-1 (KIM-1) gene expression and inhibited 
      TLR-4 (Toll-like receptor-4)/NFkappaB (nuclear factor kappa B) signalling pathway. As 
      well, GL treatment significantly decreased the pro-inflammatory mediator; IL-1beta 
      (interleukin-1 beta) level and fibrosis-associated growth factors; FGF-23 
      (fibroblast growth factor-23) and TGFbeta-1 (transforming growth factor beta-1) 
      levels. In addition, GL remarkably inhibited (Bax) the pro-apoptotic protein and 
      induced (Bcl-2) the anti-apoptotic protein expression in kidneys. Moreover, GL 
      treatment significantly alleviates kidney injury indicated by correcting the 
      deteriorated kidney function and improving oxidative stress status in DN rats. 
      CONCLUSIONS: GL significantly improved renal function indices through 
      dose-dependent kidney function restoration, oxidative stress reduction, 
      down-regulation of gene expression of KIM-1 and TLR4/NFkappaB signalling pathway 
      blockage with subsequent alleviation of renal inflammation and fibrosis.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the Royal 
      Pharmaceutical Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Hassan, Hanan M
AU  - Hassan HM
AUID- ORCID: 0000-0003-0464-0809
AD  - Department of pharmacology and Biochemistry, Faculty of Pharmacy, Delta 
      University for Science and Technology, Gamasa City, Mansoura, Egypt.
FAU - Mahran, Yasmen F
AU  - Mahran YF
AUID- ORCID: 0000-0002-6306-5616
AD  - Department of Pharmaceutical Sciences, Faculty of Pharmacy, Princess Nourah bint 
      Abdulrahman University, Riyadh, Kingdom of Saudi Arabia.
AD  - Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt.
FAU - Ghanim, Amal M H
AU  - Ghanim AMH
AD  - Department of Biochemistry, Faculty of Pharmacy, Fayoum University, Fayoum, 
      Egypt.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Biological Products)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Havcr1protein, rat)
RN  - 0 (NF-kappa B)
RN  - 0 (Rela protein, rat)
RN  - 0 (Tgfb1 protein, rat)
RN  - 0 (Tlr4 protein, rat)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Transcription Factor RelA)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 7Q7P4S7RRE (Fibroblast Growth Factor-23)
SB  - IM
MH  - Animals
MH  - Biological Products/pharmacology/therapeutic use
MH  - Cell Adhesion Molecules/metabolism
MH  - Diabetes Mellitus, Experimental/complications/drug therapy/*metabolism
MH  - Diabetic Nephropathies/drug therapy/*metabolism
MH  - Down-Regulation
MH  - Fibroblast Growth Factor-23/metabolism
MH  - Fibrosis
MH  - Inflammation/drug therapy/metabolism
MH  - Kidney/*drug effects/metabolism/pathology
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Oxidative Stress/drug effects
MH  - Rats, Sprague-Dawley
MH  - *Reishi
MH  - Signal Transduction
MH  - Toll-Like Receptor 4/*metabolism
MH  - Transcription Factor RelA/metabolism
MH  - Transforming Growth Factor beta1/*metabolism
MH  - Rats
OTO - NOTNLM
OT  - Ganoderma lucidum
OT  - FGF-23
OT  - TGFbeta-1
OT  - diabetic nephropathy
OT  - inflammation
OT  - renal fibrosis
EDAT- 2021/04/14 06:00
MHDA- 2022/01/11 06:00
CRDT- 2021/04/13 08:52
PHST- 2020/08/12 00:00 [received]
PHST- 2021/03/18 00:00 [accepted]
PHST- 2021/04/14 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/04/13 08:52 [entrez]
AID - 6224885 [pii]
AID - 10.1093/jpp/rgab058 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2021 Aug 12;73(9):1250-1261. doi: 10.1093/jpp/rgab058.